[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352784-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352784-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-analysis-identifies-fkbp10-as-a-regulator-of-tumor-immunosuppression-and-therapeutic-response","Pan-cancer analysis identifies FKBP10 as a regulator of tumor immunosuppression and therapeutic response","","Tumor immune regulation relies on intrinsic molecular mechanisms, tumor metabolic states, and the immune microenvironment. FK506-binding protein 10 (FKBP10), an ER-localized isomerase critical for extracellular matrix homeostasis, has unclear systemic roles in cancer immunity and treatment response. A pan-cancer analysis across 33 TCGA tumor types integrates copy number, methylation, and mutation data with immune-infiltration tools, and links FKBP10 to metabolic reprogramming, ECM remodeling, EMT, and programmed cell death pathways, then evaluates therapeutic sensitivity using breast assays and GDSC data.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-analysis-identifies-fkbp10-as-a-regulator-of-tumor-immunosuppression-and-therapeutic-response/352784/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-identifies-fkbp10-as-a-regulator-of-tumor-immunosuppression-and-therapeutic-response/352784.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn Holloway","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is FKBP10 and why is it relevant to cancer immunoregulation?","Question",{"text":63,"@type":64},"FKBP10 is an ER-resident peptidyl-prolyl cis–trans isomerase involved in collagen organization, protein folding, and stress responses. The study targets its role in tumor immunity and treatment response, which was previously not clearly defined.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What data and analytical approaches are used in the pan-cancer analysis?",{"text":68,"@type":64},"The analysis integrates TCGA copy number variation, DNA methylation, and mutation data across 33 tumor types. It assesses immune infiltration and immunosuppressive phenotypes with ESTIMATE, ImmuCellAI, and TIMER2, and uses pathway enrichment to connect FKBP10 to related signaling and metabolic programs.",{"name":70,"@type":61,"acceptedAnswer":71},"How is FKBP10 expression linked to prognosis and therapeutic sensitivity?",{"text":72,"@type":64},"FKBP10 is upregulated in multiple cancers and associated with poor prognosis. High FKBP10 expression correlates with an immunosuppressive microenvironment and reduced sensitivity to several chemotherapeutic agents, while in vitro experiments support its role in promoting tumor proliferation and clonogenicity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352784,1790654668,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Translational Oncology 67 (2026) 102749  \nContents lists available at ScienceDirect Translational Oncology  \njournal [homepage:](homepage: www.elsevier.com/locate/tranon)[ www.elsevier.com/locate/tranon](homepage: www.elsevier.com/locate/tranon)  \n| Pan-cancer analysis identifies FKBP10 as a regulator of tumor immunosuppression and therapeutic response\u003Cbr>Yan Li a,b,1, Jian Chen a,1, Siyan Lib , Gang Tu a,*, Lingfeng Tang a,*\u003Cbr>a Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China\u003Cbr>b Department of Breast and Thyroid Surgery, The Second People's Hospital of Yibin, 644000, Sichuan, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Key words: FKBP10\u003Cbr>Tumor cell fate Programmed cell death Therapeutic response Pan-cancer |  | Background: Tumor immune regulation depends on interactions between intrinsic molecular mechanisms, tumor cell metabolic states, and the immune microenvironment. The ER‑localized isomerase FK506‑binding protein 10 (FKBP10) is essential for extracellular matrix homeostasis, but its systemic role in cancer immune regulation and therapeutic response remains unclear.\u003Cbr>Methods: A pan‑cancer analysis of 33 TCGA tumor types integrated copy number variation, DNA methylation, and mutation data to elucidate FKBP10 regulation. ESTIMATE, ImmuCellAI, and TIMER2 assessed immune infiltration and immunosuppressive phenotypes, and pathway enrichment identified FKBP10‑related metabolic reprogramming, ECM remodeling, EMT, and programmed cell death signals. Therapeutic response was evaluated using breast cancer in vitro assays and GDSC drug sensitivity data.\u003Cbr>Results: FKBP10 was significantly upregulated in multiple cancers, especially breast and renal carcinoma, and strongly associated with poor prognosis. Its high expression was mainly driven by promoter hypomethylation and copy number amplification. FKBP10‑high tumors showed enhanced ECM remodeling, metabolic reprogramming, and apoptosis resistance, accompanied by an immunosuppressive microenvironment with reduced cytotoxic T cells and enrichment of myeloid‑derived suppressor cells and cancer‑associated fibroblasts. High FKBP10 expression also correlated with decreased sensitivity to several chemotherapeutic agents. In vitro experiments confirmed that FKBP10 promotes tumor cell proliferation and clonogenicity.\u003Cbr>Conclusions: FKBP10 is closely linked to tumor progression and treatment response by contributing to metabolic reprogramming, immunosuppressive microenvironment modulation, and programmed cell death regulation, supporting its potential as a biomarker and therapeutic target for predicting prognosis, treatment response, and immunotherapy outcomes. |\n\nIntroduction  \nAs a primary cause of global mortality, cancer represents a substantial public health issue. Despite significant progress in standard treatments like chemotherapy, radiotherapy, and surgery, along with the advent of novel approaches such as immunotherapy and targeted therapies, numerous cancers remain refractory to therapy. These malignancies are characterized by frequent relapse and metastatic dissemination [1]. Consequently, an urgent requirement exists for the discovery of new biomarkers and therapeutic avenues to enhance early detection, refine prognostic risk assessment, and augment the  \neffectiveness of treatments for diverse cancer types [2].  \nThe FK506-binding protein 10 (FKBP10) is an endoplasmic reticulum–resident peptidyl-prolyl cis–trans isomerase belonging to the FKBP family and has been implicated in collagen organization, protein folding, and cellular stress responses [3]. FKBP10 was initially studied in the context of rare genetic disorders such as Bruck syndrome and osteogenesis imperfecta, where mutations in this gene are associated with severe skeletal abnormalities [4–6]. However, the involvement of FKBP10 ","cbCaii72CxhZObzk","https://ap.wps.com/l/cbCaii72CxhZObzk","pdf",8476187,14,"English","# Introduction\n# Background\n## FKBP10 overview","[{\"question\":\"What is FKBP10 and why is it relevant to cancer immunoregulation?\",\"answer\":\"FKBP10 is an ER-resident peptidyl-prolyl cis–trans isomerase involved in collagen organization, protein folding, and stress responses. The study targets its role in tumor immunity and treatment response, which was previously not clearly defined.\"},{\"question\":\"What data and analytical approaches are used in the pan-cancer analysis?\",\"answer\":\"The analysis integrates TCGA copy number variation, DNA methylation, and mutation data across 33 tumor types. It assesses immune infiltration and immunosuppressive phenotypes with ESTIMATE, ImmuCellAI, and TIMER2, and uses pathway enrichment to connect FKBP10 to related signaling and metabolic programs.\"},{\"question\":\"How is FKBP10 expression linked to prognosis and therapeutic sensitivity?\",\"answer\":\"FKBP10 is upregulated in multiple cancers and associated with poor prognosis. High FKBP10 expression correlates with an immunosuppressive microenvironment and reduced sensitivity to several chemotherapeutic agents, while in vitro experiments support its role in promoting tumor proliferation and clonogenicity.\"}]","Pan-cancer analysis identifies FKBP10 as a regulator of tumor immunosuppression and therapeutic response | PDF",1790101368,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38998bef80a5d1530dd354ba43f317c1.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84ce2fd27f1b509a8c02b7c5f49ec08d.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42c3e0676e867e3f9ecff68fd8fde93e.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad84eccea82753ecfa53284a13cb053f.webp",980,1306]